New Tools for the Diagnosis, Prognosis and Treatment Follow-up in Chagas Disease (BIOMARCHA)

Barcelona Centre for International Health Research

Status

Completed

Conditions

Chagas Disease

Treatments

Drug: Benznidazole

Study type

Observational

Funder types

Other

Identifiers

NCT01755377

BIOMARCHA

Details and patient eligibility

About

Chagas disease is endemic to Latin America, and is of emerging importance in non-endemic countries because migration of people infected with T. cruzi. Current methods for diagnosis of T. cruzi infection are not ideal. Existing drugs for treatment are very limited, produce severe side-effects, and their effectiveness cannot be properly evaluated. Reliable biomarkers for prognosis, early diagnosis and effectiveness of treatment will be investigated.

Enrollment

63 patients

Sex

All

Ages

18 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Patients from endemic areas (Latin America)
Older than 18 years old and younger than 50
With serological confirmation of Chagas Disease infection with two different techniques
Indeterminate or initial cardiac form
No previously treated for Chagas Disease

Exclusion criteria

Co-morbidity: previous cardiac disease from other aetiology (ischemic, alcoholic or hypertensive), active inflammatory or immunology diseases for another agent. Hepatic disfunction
Pregnancy or lactation